(Q34627931)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285983%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

title

PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285983%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

main subject

angiogenesis inhibitor

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285983%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

author name string

K Dredge

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285983%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

E Hammond

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285983%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

P Handley

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285983%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

T J Gonda

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285983%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

C Vincent

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285983%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

R Brandt

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285983%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

V Ferro

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285983%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

I Bytheway

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285983%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

language of work or name

English

0 references

publication date

1 February 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285983%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

21 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285983%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

volume

104

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285983%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

635-642

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285983%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285983%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/bjc.2011.11

21 January 2020

exact match

0 references

cites work

An open letter to the FDA and other regulatory agencies: Preclinical drug development must consider the impact on metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049593

Heparin/heparan sulphate-based drugs

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049593

Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049593

Synthesis and biological evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis and tumor growth

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049593

The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049593

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049593

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049593

Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049593

Expression of heparanase in renal cell carcinomas: implications for tumor invasion and prognosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049593

Metastasis: recent discoveries and novel treatment strategies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049593

Angiogenesis: an organizing principle for drug discovery?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049593

Heparanase: a target for drug discovery in cancer and inflammation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049593

A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049593

Low-molecular-weight heparins and angiogenesis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049593

Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049593

Angiogenesis in life, disease and medicine

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049593

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049593

Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049593

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049593

Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049593

Angiogenesis and tumor metastasis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049593

Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049593

Inhibition of tumor metastasis by heparanase inhibiting species of heparin.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049593

Heparanases and tumor metastasis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049593

Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88).

7 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.11

Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.11

Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.11

Expression and clinical significance of heparanase in neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.11

Quantitative and qualitative in vivo angiogenesis assay.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049593

Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage

26 October 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.11

Expression of heparanase in hepatocellular carcinoma has prognostic significance: a tissue microarray study

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21285983

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Heparanase and vascular endothelial growth factor expression in the progression of oral mucosal melanoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21285983

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BJC.2011.11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285983%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

21 January 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21285983%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference